<DOC>
	<DOCNO>NCT01659346</DOCNO>
	<brief_summary>Every patient HCC ( Hepato-Cellular Carcinoma ) main portal vein thrombosis screen presence large esophageal varix randomize non-selective beta blocker versus primary endoscopic variceal ligation . They follow assess rate reduction index bleed rate well survival difference group .</brief_summary>
	<brief_title>Non-selective Beta Blockers Versus EVL Primary Prophylaxis Esophageal Variceal Bleeding Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<criteria>Patients cirrhosis Hepatocellular carcinoma portal vein thrombosis Presence large oesophageal varix small high risk Any contraindication betablockers Any Endoscopic Variceal Ligation Sclerotherapy within last 3 month High risk gastric varix Any past history Transhepatic Intrajugular Portosystemic Shunt surgery portal hypertension Significant cardio pulmonary comorbidity Any extrahepatic malignancy Patients past history variceal bleed Patients nontumor portal vein thrombosis Refusal participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>